Press release
Uterine Serous Carcinoma Market to Reach USD 2.7 Billion by 2034
Uterine Serous Carcinoma
Pune, India, November 2025 - According to Exactitude Consultancy, the Global Uterine Serous Carcinoma (USC) Market is projected to reach USD 2.7 billion by 2034, growing at a CAGR of 6.9% from 2025 to 2034. The market is witnessing strong growth owing to rising endometrial cancer incidence, improved molecular profiling, and increased use of combination immunotherapies for managing high-grade serous carcinoma (HGSC) of the uterus.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72873
Uterine serous carcinoma, though accounting for only about 10% of all endometrial cancers, represents nearly 40% of endometrial cancer deaths globally due to its aggressive nature and tendency for recurrence. Innovations in HER2-targeted treatments, checkpoint inhibitors, and biomarker-based diagnostics are reshaping patient outcomes and treatment pathways.
Key Takeaways
• Market Size: USD 1.4 billion in 2024 → projected USD 2.7 billion by 2034
• CAGR: 6.9% (2025-2034)
• Leading Players: Merck & Co., Roche Holding AG, Eisai Co. Ltd., AstraZeneca, GlaxoSmithKline (GSK), Pfizer Inc., Novartis AG, Bristol-Myers Squibb, and Amgen Inc.
• Primary Growth Drivers: Increased incidence of high-grade uterine cancers, rise in diagnostic accuracy, and expansion of targeted immunotherapy approvals
• Fastest-Growing Region: North America (35% market share), followed by Asia-Pacific (CAGR More than 7.5%)
Market Story
The uterine serous carcinoma treatment landscape is transforming with the approval of immuno-oncology drugs and HER2-targeted therapies. Merck's Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) has demonstrated substantial efficacy in recurrent endometrial cancer, while Roche's Herceptin (trastuzumab) has become a standard component of care in HER2-positive USC.
Molecular testing for p53 mutations, MSI-H, and HER2 expression is now routinely used to tailor therapies, improving survival rates. The focus on personalized oncology and liquid biopsy diagnostics is driving market evolution, alongside increased awareness of early screening for postmenopausal women.
Market Segmentation
By Therapy Type:
• Chemotherapy (Carboplatin, Paclitaxel)
• Targeted Therapy (Trastuzumab, Lenvatinib)
• Immunotherapy (Pembrolizumab, Dostarlimab, Nivolumab)
• Hormone Therapy
• Combination Therapy
By Diagnostic Method:
• Histopathology
• Immunohistochemistry (IHC)
• Next-Generation Sequencing (NGS)
• Liquid Biopsy
By End User:
• Hospitals
• Oncology Specialty Centers
• Research Institutes
By Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
Explore Full Report here: https://exactitudeconsultancy.com/reports/72873/uterine-serous-carcinoma-market
Recent Developments
• October 2025: GSK initiated Phase III trials for Jemperli (dostarlimab) combined with chemotherapy in newly diagnosed advanced USC patients.
• August 2025: Roche presented real-world data on Herceptin-based regimens improving progression-free survival in HER2-positive USC.
• June 2025: Merck expanded access to Keytruda + Lenvima combo therapy in Asia-Pacific through regional oncology partnerships.
• April 2025: Novartis announced development of a novel PI3K inhibitor for p53-mutant uterine cancers under its precision oncology pipeline.
Expert Insight
"Uterine serous carcinoma represents one of the most challenging gynecologic malignancies due to its rapid progression and recurrence rates," said Dr. Alina Rodriguez, Senior Oncology Analyst at Exactitude Consultancy. "However, the advent of immunotherapy and HER2-directed treatment regimens is transforming survival outcomes for patients who previously had limited options."
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72873
Market Drivers
• Rising prevalence of uterine and endometrial cancers worldwide
• Increased adoption of personalized medicine and genomic profiling
• Expanding clinical trials for checkpoint inhibitors and targeted drugs
• Growing investments in women's cancer research and patient advocacy programs
Forecast and Regional Outlook
North America continues to dominate the uterine serous carcinoma market due to strong R&D investment, favorable reimbursement policies, and high diagnostic penetration. Europe follows closely with centralized cancer registries and clinical trial networks.
Meanwhile, Asia-Pacific is projected to record the fastest CAGR (7.5%), led by improving healthcare access, growing awareness of postmenopausal health, and government-backed oncology initiatives in China, Japan, and India.
Government & Institutional Initiatives
• U.S. National Cancer Institute (NCI) launched the Endometrial Cancer Precision Medicine Program to fund biomarker research.
• European Society for Gynaecological Oncology (ESGO) updated clinical practice guidelines for HER2 testing in USC.
• Japan's Ministry of Health (MHLW) approved Lenvatinib + Pembrolizumab therapy for advanced endometrial carcinoma under fast-track review.
Conclusion
The Uterine Serous Carcinoma Market is on a trajectory of scientific and commercial transformation. As precision oncology advances and immunotherapy combinations gain momentum, global treatment paradigms are shifting toward individualized, biomarker-driven care. The next decade will witness intensified collaboration between pharma companies, diagnostic innovators, and cancer foundations to improve outcomes for women facing this aggressive disease.
This report is also available in the following languages : Japanese (子宮漿液性癌市場), Korean (자궁 장액성 암 시장), Chinese (子宫浆液性癌市场), French (Marché du carcinome séreux utérin), German (Markt für seröses Uteruskarzinom), and Italian (Mercato del carcinoma sieroso uterino), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72873/uterine-serous-carcinoma-market#request-a-sample
Related Reports
Non Hormonal Contraceptives Market
https://exactitudeconsultancy.com/reports/72879/non-hormonal-contraceptives-market
Uterine leiomyosarcoma Market
https://exactitudeconsultancy.com/reports/71591/uterine-leiomyosarcoma-market
Transcatheter Embolization And Occlusion Devices Market
https://exactitudeconsultancy.com/reports/72134/transcatheter-embolization-and-occlusion-devices-market
North America Embolization Particles Market
https://exactitudeconsultancy.com/reports/72339/north-america-embolization-particles-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Uterine Serous Carcinoma Market to Reach USD 2.7 Billion by 2034 here
News-ID: 4257557 • Views: …
More Releases from Exactitude Consultancy
Partial Seizure Market to Reach USD 11.24 Billion by 2034 Driven by Rising Epile …
Pune, India - December 2025 - The global Partial Seizure Market, valued at USD 6.82 billion in 2024, is projected to reach USD 11.24 billion by 2034, growing at a 5.2% CAGR (2025-2034), according to Exactitude Consultancy. Increasing global epilepsy burden, development of new anti-seizure medications (ASMs), and expanded access to neurological diagnostics are fueling strong market growth.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72069
Market Summary
The Partial Seizure Market…
Partial Epilepsy Market to Reach USD 9.36 Billion by 2034
Pune, India - December 2025 - The global Partial Epilepsy Market, valued at USD 5.84 billion in 2024, is projected to reach USD 9.36 billion by 2034, growing at a 4.8% CAGR (2025-2034), according to Exactitude Consultancy. Rising prevalence of focal (partial) seizures, development of improved anti-epileptic drugs (AEDs), and advancements in neuroimaging and neuromodulation therapies are key growth drivers.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72067
Market Summary
The Partial…
Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market to Reach USD 1 …
Pune, India - December 2025 - The global Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market, valued at USD 6.84 billion in 2024, is projected to reach USD 19.42 billion by 2034, growing at a robust 11.0% CAGR (2025-2034), according to Exactitude Consultancy. Rapid advancements in AAV-based gene therapies, antisense oligonucleotides (ASOs), RNA-targeting technologies, and improved diagnostic pathways are driving strong market momentum.
Download Full PDF Sample Copy of Market…
Prediabetes Market to Reach USD 29.84 Billion by 2034 Driven by Rising Global Di …
Pune, India - December 2025 - The global Prediabetes Market, valued at USD 14.62 billion in 2024, is projected to reach USD 29.84 billion by 2034, growing at a 7.2% CAGR (2025-2034), according to Exactitude Consultancy. The rising prevalence of insulin resistance, sedentary lifestyles, obesity, and increased screening initiatives are fueling substantial market growth.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/72063
Market Summary
The Prediabetes Market is expanding rapidly as healthcare…
More Releases for Uterine
Uterine Fibroids Symptoms
USA Fibroids Center is here to offer detailed information on https://www.usafibroidcenters.com/blog/uterine-fibroids-symptoms/ and help you discuss the best treatments for uterine fibroids at the clinic.
Find out the best Fibroid Treatment for you!
Treatments for uterine fibroids are accessed in women with problems related to them and show symptoms such as heavy menstrual bleeding, pain or pressure in the pelvis, or infertility and sterility.
…
Bharath Hospital Kottayam Offers Minimally Invasive Treatment for Uterine Fibroi …
Bharath Hospital Kottayam is excited introduce the latest advancement in women's healthcare - the Uterine Fibroid Embolization (UFE) treatment. Uterine fibroids are non-cancerous growths that form in the uterus. They are a common condition among women, especially those of reproductive age. These tumors can vary in size, from small growths to large masses that can distort the shape of the uterus. Although many women with uterine fibroids experience no symptoms,…
Uterine Manipulator Devices Market Report 2018: Segmentation by Type (Donnez Typ …
Global Uterine Manipulator Devices market research report provides company profile for ConMed, Richard Wolf, Bisinger, Planmeca Oy, Ethicon Endosurgery, Cooper Surgical, Hospiiniz International, C. R. Bard and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025,…
Uterine Fibroids Treatment Market : Hysterectomy to Remain Most Preferred Uterin …
The market for uterine fibroids treatment market is fragmented in nature with a high number of players operating in it across the U.S., states a new market research report by Transparency Market Research. The estimated entry of new players and the increasing research and development activities are some of the key factors that are projected to strengthen the competitive scenario of the market throughout the forecast period. The leading players…
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018 - Research By Ma …
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.
Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers…
Uterine Fibroids Treatment Market: Rising Prevalence of Uterine Fibroids amongst …
The high prevalence of uterine fibroids across the U.S. has created a significant demand for uterine fibroid treatments across the countries. The growing public concern about the occurrence of uterine fibroids, which are also called uterine leiomyoma, have propelled the demand for treatments and solutions to alleviate the pain, excessive bleeding, and pelvic discomfort.
According to the report by Transparency Market Research, the U.S. uterine fibroid treatment market is anticipated to…
